TWI309164B - Novel crystal form b of a known thiophenecarboxylic acid dodecahydrocyclopenta[a]phenanthrenyl ester,pharmaceutical composition comprising the same,use thereof, and method of preparing it - Google Patents
Novel crystal form b of a known thiophenecarboxylic acid dodecahydrocyclopenta[a]phenanthrenyl ester,pharmaceutical composition comprising the same,use thereof, and method of preparing it Download PDFInfo
- Publication number
- TWI309164B TWI309164B TW092120513A TW92120513A TWI309164B TW I309164 B TWI309164 B TW I309164B TW 092120513 A TW092120513 A TW 092120513A TW 92120513 A TW92120513 A TW 92120513A TW I309164 B TWI309164 B TW I309164B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- crystalline form
- formula
- pharmaceutical composition
- inflammatory
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 239000013078 crystal Substances 0.000 title 1
- -1 phenanthrenyl ester Chemical class 0.000 title 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0217504.0A GB0217504D0 (en) | 2002-07-29 | 2002-07-29 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200401633A TW200401633A (en) | 2004-02-01 |
| TWI309164B true TWI309164B (en) | 2009-05-01 |
Family
ID=9941275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092120513A TWI309164B (en) | 2002-07-29 | 2003-07-28 | Novel crystal form b of a known thiophenecarboxylic acid dodecahydrocyclopenta[a]phenanthrenyl ester,pharmaceutical composition comprising the same,use thereof, and method of preparing it |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7683048B2 (enExample) |
| EP (2) | EP1554303B1 (enExample) |
| JP (1) | JP2006501207A (enExample) |
| KR (1) | KR100688371B1 (enExample) |
| CN (1) | CN1305892C (enExample) |
| AR (1) | AR040692A1 (enExample) |
| AT (1) | ATE349459T1 (enExample) |
| AU (1) | AU2003251651B2 (enExample) |
| BR (1) | BR0313044A (enExample) |
| CA (1) | CA2493330C (enExample) |
| CY (1) | CY1106406T1 (enExample) |
| DE (1) | DE60310747T2 (enExample) |
| DK (1) | DK1554303T3 (enExample) |
| EC (1) | ECSP055579A (enExample) |
| ES (1) | ES2279970T3 (enExample) |
| GB (1) | GB0217504D0 (enExample) |
| HK (1) | HK1080484B (enExample) |
| IL (2) | IL166287A0 (enExample) |
| MX (1) | MXPA05001173A (enExample) |
| MY (1) | MY136407A (enExample) |
| NO (1) | NO20050806L (enExample) |
| NZ (2) | NZ537868A (enExample) |
| PE (1) | PE20040722A1 (enExample) |
| PL (1) | PL209409B1 (enExample) |
| PT (1) | PT1554303E (enExample) |
| RU (2) | RU2348646C1 (enExample) |
| SI (1) | SI1554303T1 (enExample) |
| TW (1) | TWI309164B (enExample) |
| WO (1) | WO2004013156A1 (enExample) |
| ZA (1) | ZA200500370B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| AU7576001A (en) | 2000-08-05 | 2002-02-18 | Glaxo Group Ltd | 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| WO2002088167A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0523654D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0603783D0 (en) * | 2006-02-24 | 2006-04-05 | Novartis Ag | Organic compounds |
| CN103622962A (zh) * | 2008-03-14 | 2014-03-12 | 大塚制药株式会社 | 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的纤维症的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU550939A1 (ru) * | 1975-05-19 | 1994-07-15 | Институт химии древесины АН ЛатвССР | 1,2,3,4,4а,4в,5,6,10,10а -декагидро -6- хлорацетоксиметил -1,4а-диметил -7- (1-метилэтил) -1- фенантренкарбоновая кислота или ее соли |
| JPH08291073A (ja) * | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 医薬品組成物及びその製造方法 |
| GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
-
2002
- 2002-07-29 GB GBGB0217504.0A patent/GB0217504D0/en not_active Ceased
-
2003
- 2003-07-25 PE PE2003000741A patent/PE20040722A1/es not_active Application Discontinuation
- 2003-07-25 AR AR20030102680A patent/AR040692A1/es unknown
- 2003-07-28 TW TW092120513A patent/TWI309164B/zh not_active IP Right Cessation
- 2003-07-28 AU AU2003251651A patent/AU2003251651B2/en not_active Ceased
- 2003-07-28 NZ NZ537868A patent/NZ537868A/en unknown
- 2003-07-28 MY MYPI20032832A patent/MY136407A/en unknown
- 2003-07-28 MX MXPA05001173A patent/MXPA05001173A/es active IP Right Grant
- 2003-07-28 CA CA2493330A patent/CA2493330C/en not_active Expired - Fee Related
- 2003-07-28 WO PCT/EP2003/008314 patent/WO2004013156A1/en not_active Ceased
- 2003-07-28 CN CNB038180596A patent/CN1305892C/zh not_active Expired - Fee Related
- 2003-07-28 AT AT03766325T patent/ATE349459T1/de active
- 2003-07-28 US US10/522,358 patent/US7683048B2/en not_active Expired - Fee Related
- 2003-07-28 JP JP2004525343A patent/JP2006501207A/ja active Pending
- 2003-07-28 HK HK06100247.5A patent/HK1080484B/en not_active IP Right Cessation
- 2003-07-28 RU RU2007143025/04A patent/RU2348646C1/ru not_active IP Right Cessation
- 2003-07-28 EP EP03766325A patent/EP1554303B1/en not_active Expired - Lifetime
- 2003-07-28 ES ES03766325T patent/ES2279970T3/es not_active Expired - Lifetime
- 2003-07-28 DE DE60310747T patent/DE60310747T2/de not_active Expired - Lifetime
- 2003-07-28 PL PL373140A patent/PL209409B1/pl not_active IP Right Cessation
- 2003-07-28 RU RU2005105688/04A patent/RU2330043C2/ru not_active IP Right Cessation
- 2003-07-28 SI SI200330721T patent/SI1554303T1/sl unknown
- 2003-07-28 BR BR0313044-4A patent/BR0313044A/pt not_active IP Right Cessation
- 2003-07-28 KR KR1020057001581A patent/KR100688371B1/ko not_active Expired - Fee Related
- 2003-07-28 EP EP06005390A patent/EP1676854A1/en not_active Withdrawn
- 2003-07-28 PT PT03766325T patent/PT1554303E/pt unknown
- 2003-07-28 NZ NZ549713A patent/NZ549713A/en unknown
- 2003-07-28 DK DK03766325T patent/DK1554303T3/da active
-
2005
- 2005-01-13 IL IL16628705A patent/IL166287A0/xx unknown
- 2005-01-14 ZA ZA200500370A patent/ZA200500370B/en unknown
- 2005-01-26 EC EC2005005579A patent/ECSP055579A/es unknown
- 2005-02-15 NO NO20050806A patent/NO20050806L/no unknown
-
2007
- 2007-03-22 CY CY20071100400T patent/CY1106406T1/el unknown
- 2007-07-26 IL IL184848A patent/IL184848A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6800643B2 (en) | Mixtures for organic compounds for the treatment of airway diseases | |
| AU2011287711B2 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| CN102946868B (zh) | 包含抗毒蕈碱药的干粉制剂 | |
| TWI309164B (en) | Novel crystal form b of a known thiophenecarboxylic acid dodecahydrocyclopenta[a]phenanthrenyl ester,pharmaceutical composition comprising the same,use thereof, and method of preparing it | |
| WO2009090008A1 (en) | Dry powder formulation comprising an anticholinergic drug | |
| TW200817333A (en) | Organic compounds | |
| JP6366696B2 (ja) | Ｓ−［４−（３−フルオロ−３−メチルブチリルオキシ）ブタ−２−イニル］６α，９α−ジフルオロ−１７α−（フラン−２−イル）カルボニルオキシ−１１β−ヒドロキシ−１６α−メチル−３−オキソアンドロスタ−１，４−ジエン−１７β−カルボチオアートを使用する炎症性病態の治療の方法 | |
| KR20150100902A (ko) | 옥시부티닌의 투여를 위한 방법 및 조성물 | |
| CN116730851A (zh) | 一种维兰特罗盐型化合物及其制备方法和用途 | |
| HK1059564B (en) | Indanylderivatives for treating airway diseases | |
| HK1108364A (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |